Network modulation following sham surgery in Parkinson’s disease
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Patient responses to placebo and sham effects are a major obstacle to the development of therapies for brain disorders, including Parkinson's disease (PD). Here, we used functional brain imaging and network analysis to study the circuitry underlying placebo effects in PD subjects randomized to sham surgery as part of a double-blind gene therapy trial. Metabolic imaging was performed prior to randomization, then again at 6 and 12 months after sham surgery. In this cohort, the sham response was associated with the expression of a distinct cerebello-limbic circuit. The expression of this network increased consistently in patients blinded to treatment and correlated with independent clinical ratings. Once patients were unblinded, network expression declined toward baseline levels. Analogous network alterations were not seen with open-label levodopa treatment or during disease progression. Furthermore, sham outcomes in blinded patients correlated with baseline network expression, suggesting the potential use of this quantitative measure to identify "sham-susceptible" subjects before randomization. Indeed, Monte Carlo simulations revealed that a priori exclusion of such individuals substantially lowers the number of randomized participants needed to demonstrate treatment efficacy. Individualized subject selection based on a predetermined network criterion may therefore limit the need for sham interventions in future clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deep Brain Stimulation for Treatment-Resistant Depression
Mayberg, H. S., Lozano, A. M., Voon, V., McNeely, H. E., Seminowicz, D., Hamani, C., Schwalb, J. M., & Kennedy, S. H. (2005) · Neuron · doi:10.1016/j.neuron.2005.02.014 · Cited by 4,059
Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space
Collins, D. L., Neelin, P., Peters, T. M., & Evans, A. C. (1994) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-199403000-00005 · Cited by 3,431
Benedict, R. H. B., Schretlen, D., Groninger, L., & Brandt, J. (1998) · The Clinical Neuropsychologist · doi:10.1076/clin.12.1.43.1726 · Cited by 1,597
Placebo and Opioid Analgesia-- Imaging a Shared Neuronal Network
Petrovic, P., Kalso, E., Petersson, K. M., & Ingvar, M. (2002) · Science · doi:10.1126/science.1067176 · Cited by 1,488
Stoodley, C. J., & Schmahmann, J. D. (2010) · Cortex · doi:10.1016/j.cortex.2009.11.008 · Cited by 1,360 · cited 1×
“This region, which is the major cerebellar target of afferent projections from the amygdala and from the paralimbic cingulate and parahippocampal cortex, has been linked to affective processing in both health and disease (20).”
The basal ganglia communicate with the cerebellum
Bostan, A. C., Dum, R. P., & Strick, P. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000496107 · Cited by 780
O'Reilly, J. X., Beckmann, C. F., Tomassini, V., Ramnani, N., & Johansen-Berg, H. (2010) · Cerebral Cortex · doi:10.1093/cercor/bhp157 · Cited by 738 · cited 1×
“Indeed, the spatial proximity of the cerebellar SSRP node to the sensorimotor zones of the anterior vermis (lobules V and VI) (21) is consistent with the motoric specificity of the sham response in this study.”
LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70039-4 · Cited by 681
Self-citationThe placebo response in medicine: minimize, maximize or personalize?
Enck, P., Bingel, U., Schedlowski, M., & Rief, W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3923 · Cited by 671
Petrovic, P., Dietrich, T., Fransson, P., Andersson, J., Carlsson, K., & Ingvar, M. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.023 · Cited by 437 · cited 1×
“Indeed, changes in these and related brain regions have been found to accompany placebo effects occurring in the context of emotional processing (10, 16).”
Placebo effects: clinical aspects and neurobiology
Oken, B. S. (2008) · Brain · doi:10.1093/brain/awn116 · Cited by 237
Furmark, T., Appel, L., Henningsson, S., Åhs, F., Faria, V., Linnman, C., Pissiota, A., Frans, Ö., Bani, M., Bettica, P., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2534-08.2008 · Cited by 210 · cited 2×
“Indeed, changes in these and related brain regions have been found to accompany placebo effects occurring in the context of emotional processing (10, 16).”
Multivariate data analysis for neuroimaging data: overview and application to Alzheimer’s disease
Initiative, T. A. D. N., Habeck, C., & Stern, Y. (2010) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-010-9093-0 · Cited by 127 · cited 3×
“In OrT/CVA, as in other forms of spatial covariance analysis, the significance of the resulting topographies is assessed using nonparametric tests (46).”
Influential
Cited by
Brakedal, B., Dölle, C., Riemer, F., Ma, Y., Nido, G. S., Skeie, G. O., Craven, A. R., Schwarzlmüller, T., Brekke, N., Diab, J., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.02.001 · Cited by 323
Self-citationLong-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson’s disease
Niethammer, M., Tang, C. C., LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Sarkar, A., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.90133 · Cited by 124
Self-citationPromising therapeutic agents for the treatment of Parkinson’s disease
Majláth, Z., Török, N., Toldi, J., & Vécsei, L. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1164687 · Cited by 7
Metadata
- Authors
- Ko, J. H., Feigin, A., Mattis, P. J., Tang, C. C., Ma, Y., Dhawan, V., During, M. J., Kaplitt, M. G., & Eidelberg, D.
- Venue
- Journal of Clinical Investigation
- Published
- 2014-07-18
- Volume
- 124
- Issue
- 8
- Pages
- 3656-3666
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2086482577
- Cited by
- 91
- References
- 13
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.